Emerging Markets Webinar: Collaborating with China - Perspectives from a Real-Life Cross-Border Transaction in the Medical Device Industry
[On Demand Webinar - DL1063]
Course Type: Audio / PowerPoint Presentation
Course Registration Fee: Lex Mundi Member Fee: No Charge / Non-Member Fee: No Charge
Duration: 90 minutes
Technology collaboration with companies in China is no longer a myth. In this presentation, Response Biomedical, a public medical device company in Canada, entered a complex collaboration deal with a local Chinese company for equity investment, regulatory approval, manufacture, and technology transfer and co-development.
In this program, the CEO of Response and Jun He (Lex Mundi member firm for China) counsels involved in this deal share the insights of this Canadian-China medical device deal and discuss the issues in gaining regulatory approval in China, corporate translation, importing/exporting laws, and IP protection in China. In addition to legal issues, the panel will elaborate on culture and business considerations for companies on both sides in dealing with cross-border transactions. While technology collaborations with companies in China are only a matter of time, the audience will learn the lessons and challenges of this real deal and the complexities involved in this fast-growing new territory.
What You Will Learn:
- Become aware of the issues in importing/exporting laws as well as the regulatory and licensing requirements in cross-border technology collaboration in the medical devices sector
- Clearly defining your intellectual property, what to be licensed, what scope, what should be independently developed, what would be kept; and what should be co-developed with your partners in China
- Be aware of cultural and practice difference; negotiating with your partner is also an education process for your partner
Joe has extensive expertise in strategic acquisitions and private equity investment. His services range from structure design, legal due diligence, preparation of transaction documents, negotiation, closing and up to post-closing matters. He has advised clients (including multinational companies, buy-out funds, PE/VC funds, etc.) on many high-profile cross-border acquisitions and joint venture projects in healthcare sector. Asialaw has recognized him as a Leading Lawyer in the area of corporate/M&A.
Dr. Barbara R. Kinnaird has over 20 years of research and business experience primarily in the fields of point of care (POC) testing and in vitro diagnostics. Since joining Response Biomedical Corp. in August 2004, Dr. Kinnaird has held several key management positions including responsibilities for Product Development, Quality, Regulatory, Manufacturing and Sales. During Dr. Kinnaird’s tenure in these positions, she has improved the product design control, operational efficiencies, gross margins and sales. Additionally under her direction, the Company obtained regulatory approvals to support sales in several global jurisdictions such as China, Japan, United States and Canada.
Dr. Kinnaird holds a Ph.D. in Microbiology and Immunology from the University of British Columbia at the B.C. Children’s Hospital in the Department of Pediatrics. She conducted her post-doctoral research at the Michael Smith Laboratories in genomics and gene expression profiling, in collaboration with the B.C. Genome Sciences Centre and consulted for the Proteomics division of Incyte Genomics Inc.
Frank Zhou is a partner of the Jun He Law Offices. He is based in the Shanghai office. Mr. Zhou has more than 13 years experience in assisting international clients to invest in and develop their business in China. He has extensive experience in the regulatory and corporate matters in the healthcare sector. He is the outside counsel for more than 10 multinational companies operating in China, including Johnson & Johnson, BD, Bracco Sine, Yangtze Pharma Group etc.
James "Jian" Zhu, Ph.D., is a partner at Jun He Law Offices with the mission of growing the firm’s patent practice in China. James is known for his innovative legal approach to solving business problems and charting clients through rapidly evolving environment in China.
James' practice includes patent litigation, procurement, opinion, strategies, technology licensing, primarily focusing on life sciences, material sciences, medical devices, and electronics. As a conduit between China and outside, James provides strategic patent counselling for clients in their entry into the Chinese market, conducts complex due diligence in investment and M&A to minimize IP risks, spearheads licensing and technology collaboration, and enforces or defends IP rights by leading litigation effort in China. James is also a frequent author and speaker on patent protection and related intellectual property matters.s.
To obtain MCLE/CPD credit for online courses through the Lex Mundi Learning Network, please refer to your jurisdiction’s regulating agency for information regarding MCLE/CPD self-filing instructions.